Compound promiscuity: What can we learn from current data?

Drug Discovery Today

Volumn 18, Issue 13-14, 2013, Pages 644-650

  Hu, Ye ^a   Bajorath, Jürgen ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG DEVELOPMENT; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; IC 50; PREDICTION; REVIEW; STRUCTURE ACTIVITY RELATION;

ANIMALS; DRUG DISCOVERY; DRUG REPOSITIONING; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; LIGANDS; MOLECULAR STRUCTURE; MOLECULAR TARGETED THERAPY; SIGNAL TRANSDUCTION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84879892154     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2013.03.002     Document Type: Review

References (34)

1. G.V. Paolini Global mapping of pharmacological space Nat. Biotechnol. 24 2006 805 815
2. M. Campillos Drug target identification using side-effect similarity Science 321 2008 263 266
3. A.D.W. Boran, and R. Iyengar Systems approaches to polypharmacology and drug discovery Curr. Opin. Drug Discov. Dev. 13 2010 297 309
4. X. Jalencas, and J. Mestres On the origins of drug polypharmacology MedChemComm 4 2013 80 87
5. Z.A. Knight Targeting the cancer kinome through polypharmacology Nat. Rev. Cancer 10 2010 130 137
6. C.R. Chong, and D.J. Sullivan New uses for old drugs Nature 448 2006 645 646
7. A.L. Hopkins Network pharmacology: the next paradigm in drug discovery Nat. Chem. Biol. 4 2008 682 690
8. J.A. Metz, and P.J. Hajduk Rational approaches to targeted polypharmacology: creating and navigating protein-ligand interaction networks Curr. Opin. Chem. Biol. 14 2010 498 504
9. M.T. Bianchi, and E.J. Botzolakis Targeting ligand-gated ion channels in neurology and psychiatry: is pharmacological promiscuity an obstacle or an opportunity? BMC Pharmacol. 10 2010 1 8
10. P. Csermely The efficiency of multi-target drugs: the network approach might help drug design Trends Pharmacol. Sci. 4 2005 178 182
11. M.A. Yildirim Drug-target network Nat. Biotechnol. 25 2007 1119 1126
12. L. Xie Novel computational approaches to polypharmacology as a means to define responses to individual drugs Annu. Rev. Pharmacol. Toxicol. 52 2012 361 379
13. A. Bender 'Bayes affinity fingerprints' improve retrieval rates in virtual screening and define orthogonal bioactivity space: when are multitarget drugs a feasible concept? J. Chem. Inf. Model. 46 2006 2445 2456
14. A. Gaulton ChEMBL: a large-scale bioactivity database for drug discovery Nucleic Acids Res. 40 2012 D1100 D1107
15. Y. Wang PubChem's BioAssay database Nucleic Acids Res. 40 2012 D400 D412
16. J. Mestres Data completeness - the achilles heel of drug-target networks Nat. Biotechnol. 26 2008 983 984
17. C. Knox DrugBank 3.0: a comprehensive resource for 'omics' research on drugs Nucleic Acids Res. 39 2011 D1035 D1041
18. M. Olah WOMBAT and WOMBAT-PK: bioactivity databases for lead and drug discovery S.L. Schreiber, T.M. Kapoor, G. Wess, Chemical Biology: From Small Molecules to Systems Biology and Drug Design Vol. 1-3 2011 Wiley-VCH 760 786
19. J.T. Metz Navigating the kinome Nat. Chem. Biol. 7 2011 200 202
20. G.W. Bemis, and M.A. Murcko The properties of known drugs. 1. Molecular frameworks J. Med. Chem. 39 1996 2887 2893
21. M. Cases, and J. Mestres A chemogenomic approach to drug discovery: focus on cardiovascular diseases Drug Discov. Today 14 2009 479 485
22. Y. Hu, and J. Bajorath Polypharmacology directed compound data mining: identification of promiscuous chemotypes with different activity profiles and comparison to approved drugs J. Chem. Inf. Model. 50 2010 2112 2118
23. T. Liu BindingDB: a web-accessible database of experimentally determined protein-ligand binding affinities Nucleic Acids Res. 35 2007 D198 D201
24. M.J. Keiser Relating protein pharmacology by ligand chemistry Nat. Biotechnol. 25 2007 197 206
25. Molecular Drug Data Report (MDDR) 2008 Symyx Software San Ramon, CA
26. E. Lounkine Large-scale prediction and testing of drug activity on side-effect targets Nature 486 2012 361 367
27. Y. Hu, and J. Bajorath Growth of ligand-target interaction data in ChEMBL is associated with increasing and activity measurement-dependent compound promiscuity J. Chem. Inf. Model. 52 2012 2550 2558
28. Y. Hu, and J. Bajorath How promiscuous are pharmaceutically relevant compounds? A data-driven assessment AAPS J. 15 2013 104 111
29. Y. Hu, and J. Bajorath Many structurally related drugs bind different targets whereas distinct drugs display significant target overlap RSC Adv. 2 2012 3481 3489
30. P.A. Clemons Small molecules of different origins have distinct distributions of structural complexity that correlate with protein-binding profiles Proc. Natl Acad. Sci. U.S.A. 107 2010 18787 18792
31. D. Dimova Matched molecular pair analysis of small molecule microarray data identifies promiscuity cliffs and reveals molecular origins of extreme compound promiscuity J. Med. Chem. 55 2012 10220 10228
32. J. Hussain, and C. Rea Computationally efficient algorithm to identify matched molecular pairs (MMPs) in large data sets J. Chem. Inf. Model. 50 2010 339 348
33. A.B. Yongye, and J.L. Medina-Franco Data mining of protein-binding profiling data identifies structural modifications that distinguish selective and promiscuous compounds J. Chem. Inf. Model. 52 2012 2454 2461
34. N. Sturm Structural insights into the molecular basis of the ligand promiscuity J. Chem. Inf. Model. 52 2012 2410 2421